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Postoperative thiopurines in smokers with Crohn’s disease
Crohn’s disease is a lifelong disease that is often not cured 
by resection of all macroscopic lesions and nearly always 
recurs clinically within a few years after so-called curative 
surgery. Thus, a maintenance treatment is needed in 
patients who undergo surgery. Thiopurines (azathioprine 
and mercaptopurine) are the cornerstone of maintenance 
treatment in Crohn’s disease and decreased the risk of 
postoperative clinical recurrence compared with placebo 
in two randomised trials published at the beginning 
of this century.1 However, the eﬀ ect was modest; 
pooling the results from the two trials gave a risk ratio 
of 0·74 (95% CI 0·58–0·94).1 Findings from other trials 
comparing thiopurines with mesalazine did not show 
signiﬁ cant diﬀ erences.1 Moreover, impressive results were 
reported from pilot studies, showing the great eﬃ  cacy 
of anti-tumour-necrosis-factor (anti-TNF) drugs in this 
setting.2 For these reasons, and because of problems 
of tolerance in up to 20% of patients, many physicians 
became reluctant to use thiopurines as preventive 
drugs, preferring to prescribe anti-TNF drugs in patients 
with a high risk of recurrence and to give mesalazine 
or no treatment at all in low-risk patients. Thus, the 
relevance of a new trial re-investigating the beneﬁ ts of 
mercaptopurine after surgery could be questioned. 
However, the TOPPIC trial3 of mercaptopurine to 
prevent recurrence of Crohn’s disease after surgical 
resection, published in The Lancet Gastroenterology & 
Hepatology, is unique because of its high methodological 
quality, in particular its long duration of up to 3 years, 
the masking of participants, the dosing of the drug, and 
the choice of a solid and pragmatic primary endpoint of 
well deﬁ ned clinical recurrence and need for associated 
medical or surgical treatment. In the trial, 128 patients 
with Crohn’s disease received mercaptopurine and 
112 placebo. 16 (13%) patients in the mercaptopurine 
group versus 26 (23%) patients in the placebo 
group had a clinical recurrence of Crohn’s disease and 
needed anti-inﬂ ammatory rescue treatment or primary 
surgical intervention (adjusted hazard ratio [HR] 
0·54, 95% CI 0·27–1·06; p=0·07; unadjusted HR 0·53, 
95% CI 0·28–0·99; p=0·046). This ﬁ nding of reduced 
clinical recurrence with mercaptopurine is not new, but 
this result should be put in parallel with more recent 
data on anti-TNF drugs: the PREVENT study4 did not 
show a signiﬁ cant eﬀ ect of inﬂ iximab on prevention 
of postoperative clinical recurrence by month 18, and, 
although not designed for this objective, the POCER 
study5 showed that adalimumab had some eﬃ  cacy, 
but this was not as universal as expected, with 
43% of patients given adalimumab postoperatively 
experiencing endoscopic recurrence at 2 years. When 
considering long-term prescription of a drug, long-term 
tolerance and eﬃ  cacy, constraints, and costs need to be 
taken into account; this would favour thiopurines over 
anti-TNF drugs in most patients.
The key ﬁ nding of the TOPPIC trial was the particular 
eﬃ  cacy of mercaptopurine in smokers. 55 (23%) patients 
included in the study were active smokers. In this 
subgroup, mercaptopurine was eﬀ ective at preventing 
postoperative recurrence (HR 0·13, 95% CI 0·04–0·46), 
with a number needed to treat to prevent one recurrence 
of only three. Conversely, the eﬀ ect of mercaptopurine 
was not signiﬁ cant in non-smokers. Although 
unexplained, the eﬃ  cacy of thiopurines in smokers has 
been known for around 20 years.6 Smokers have a more 
severe disease than do non-smokers, and they need 
more immunosuppressants and surgery; active smoking 
is recognised as the most important predictive factor 
of disease recurrence. Because smokers have a high 
risk of early postoperative recurrence, surgery must be 
avoided or postponed as long as possible and all eﬀ orts 
are needed to achieve smoking cessation before surgery. 
That said, results of smoking cessation programmes 
are disappointing in this population. When a smoker 
needs surgery, ﬁ ndings from the TOPPIC trial3 suggest 
that thiopurines should be started or re-started within 
the 3 months after surgery, with a high probability of 
delaying postoperative recurrence.
Postoperative recurrence, with the sequence of 
histological lesions, endoscopic ulcerations, clinical 
symptoms, then re-operation, is an amazing model 
to understand the natural history of Crohn’s disease 
and to test treatments. The place of thiopurines in the 
management of Crohn’s disease has been debated during 
recent years, particularly after the two negative trials 
testing the eﬃ  cacy of azathioprine in very early Crohn’s 
disease7,8 and the evidence of an increased, albeit small, 
risk of malignancy.9 In fact, the conclusion of the RAPID 
trial7 was not that azathioprine was useless, but that 
there was no need to start azathioprine very early in the 
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disease course. Thiopurines are eﬃ  cacious in 40–50% of 
patients with Crohn’s disease. They are safe before age 
65 years and in people who test positive for Epstein-Barr 
virus, and are safe and particularly eﬃ  cacious in smokers. 
They should remain a major maintenance treatment for 
Crohn’s disease, provided that their dosing is suﬃ  cient or 
optimised.10 In this regard, it is noteworthy that the hazard 
of clinical recurrence decreased when the concentration 
of thioguanine nucleotides, a marker of compliance and 
adequate dosing, increased in the TOPPIC trial.
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A new technique to improve surgery for peritoneal colorectal 
metastases?
I congratulate Niels Harlaar and colleagues for their 
Article1 on molecular ﬂ uorescence-guided surgery for 
peritoneal carcinomatosis of colorectal origin. It is an 
exciting study with concrete implications for peritoneal 
surface surgeons. In other locoregional metastatic 
colorectal cancer sites, such as the liver and lungs, the 
most important factor to prevent a new recurrence 
and ultimately prolong survival is an R0 resection. 
In liver surgery, intraoperative ultrasound augmentation 
of the surgeon’s visual and palpation skills is common to 
improve identiﬁ cation of tumour nodules in the liver.2 
Preoperative CT staging and intraoperative ultrasound 
provide the surgeon with the detailed information 
needed to achieve precise surgical results during 
resections of colorectal liver metastases. This precision 
is very much absent in peritoneal surface surgery. 
No good preoperative radiological planning algorithms 
for peritoneal metastases exist and no intraoperative 
augmentations are available in clinical routine. Treatment 
decisions during surgery are often made intraoperatively 
according to the surgeon’s own experience,3 making 
accurate surgical precision planning diﬃ  cult. The present 
study1 is a welcome initiative to alleviate this problem. 
The issue is shown in the completeness of cytoreduction 
score, for which a score of 0 is really equivalent to an 
R1 resection, in which microscopic residual tumours are 
assumed to remain. As such, hyperthermic intraperitoneal 
chemotherapy (HIPEC) is needed to eradicate the 
microscopic disease. However, as HIPEC has become 
widely adopted as standard treatment in Sweden instead 
of systemic chemotherapy for colorectal cancer with 
peritoneal metastases, we have noticed that patients are 
getting referred earlier at our centre. Instead of receiving 
one or two lines of chemotherapy before referral, the 
patients are referred for surgery when peritoneal disease 
is discovered leading to lower peritoneal cancer index 
scores. The ability to accurately identify the exact number 
of peritoneal metastases by visual enhancement, such as 
with a ﬂ uorescent dye attached to bevacizumab, could 
substantially enhance the surgical precision of peritoneal 
surface surgeons by ensuring a good margin to each 
lesion—perhaps even achieving R0 resections.
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